NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Garuda Therapeutics

Garuda Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttp://garudatx.com/

Last Round

Series A

Extension

Mar 4, 2025

Total Funding Raised

$256M

Company Overview

Garuda Therapeutics is a biotechnology company that develops off-the-shelf hematopoietic stem cell therapies to treat blood, bone marrow, immune, and metabolic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

hematopoietic stem cellHSCcell therapyoff-the-shelf therapyregenerative medicineHLA-compatibleblood stem cellbone marrow transplantallogeneic cell therapybiotechnologyhematologic malignancytransgene-free

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Garuda Therapeutics Comparables

Compare Garuda Therapeutics with similar companies based on industry and business-model similarity.

Garuda Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Stratus Therapeutics
100%
Cell BioEngines, Inc.
87%
GC Therapeutics
77%

Garuda Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionMar 4, 2025
Series BFeb 7, 2023
Series ASep 23, 2021
Series AAug 24, 2021

Garuda Therapeutics Investors

Notable investors and investment history

Garuda Therapeutics investors
InvestorRounds
Ridgeback CapitalSeries A
Cormorant Asset ManagementSeries A, Series A Extension, Series B
Mass General Brigham InnovationSeries A, Series B
OrbiMedSeries A Extension, Series A, Series B
Cormorant CapitalSeries A
Northpond VenturesSeries A Extension, Series A, Series B
Alexandria Venture InvestmentsSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 4, 2025

    $50M raised in Series A Extension round.

  • Mar 3, 2025

    Avanish Vellanki appointed as new President and Chief Executive Officer.

Garuda Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Garuda Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Garuda Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range9
Year Founded2021
Last FundingMar 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.